Compare Arko Corp. (ARKO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Mesoblast Limited — how do they compare? Arko Corp. trades at $4.39 (market cap $493.06M), while Mesoblast Limited trades at $16.96 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 4.5× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| ARKO | MESO | |
|---|---|---|
Market Cap | $493.06M | $2.21B |
Sector | Consumer Cyclical | Technology |
52-Week High | $8.64 | $20.96 |
52-Week Low | $3.82 | $12.88 |
Enterprise Value | $2.67B | $2.21B |
Dividend Yield | 2.73% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
